Company Overview and News

22
Genetic Technologies Invited to Establish a Market Presence in Hainan, China

2018-09-17 globenewswire - 2
MELBOURNE, Australia, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Hainan Resort Software Community(“HRSC”) has on behalf of Hainan Ecological Smart City Group (“HESCG”) formally extended an invitation to Genetic Technologies Limited (“GTG”) to establish its planned market entry into China via the Hainan Free Trade Zone initiative. As previously reported to the market on 21 August 2018, participants in the Hainan Medical Pilot Zone gain access to the Chinese healthcare market with an estimated value in excess of US$800B.
GTG GNTLF GENE

21
Genetic Technologies Limited Invited by Representatives of the Hainan Government to Discuss Market Entry into China

2018-08-21 globenewswire - 1
MELBOURNE, Australia, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Representatives of the Hainan Government - Hainan Ecological Smart City Group (“HESCG”), a Chinese industrial park development & operations company have formally invited Genetic Technologies Limited (“GTG”) to visit the Hainan Medical Pilot Zone to conduct a formal review and discuss opportunities for market entry into China via the Hainan Free Trade Zone initiative.
GTG GNTLF GENE

21
Genetic Technologies Announces Proposed Joint Venture with Beijing Zishan Health Consultancy Limited

2018-08-16 globenewswire - 1
MELBOURNE, Australia, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”, “GTG”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has signed a Heads of Agreement (Agreement) with Beijing Zishan Health Consultancy Limited (Zishan). The Agreement provides a framework according to which the two parties will explore opportunities to achieve market entry, through a Joint Venture, for GTG’s genomic tests into the health sector in the People’s Republic of China.
GTG GNTLF GENE

20
Genetic Technologies Secures A$20 Million Equity Placement Facility

2018-08-08 globenewswire
MELBOURNE, Australia, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has entered into a A$20 million Equity Placement Facility (the “Facility”) with the Kentgrove Capital Growth Fund (“Kentgrove Capital”), an investment fund managed by Kentgrove Capital Pty Ltd, a Melbourne-based investment management firm, to strengthen the Company’s funding position.
GTG GNTLF GENE

20
Genetic Technologies Announces Appointment of Swisstec as Non-Exclusive Asian Distributor

2018-07-30 globenewswire
MELBOURNE, Australia, July 30, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (Nasdaq:GENE) (“Company”, “GTG”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has entered into a non-exclusive distribution agreement with Swisstec Health Analytics Ltd. (“Swisstec”). This agreement grants Swisstec the right to explore opportunities to deliver GTG’s genetic screening tests to hospital networks in Asia.
GTG GNTLF GENE

22
Genetic Technologies Limited Announces Expansion of Genetic Risk Assessment Tests and October Launch of New Breast Cancer and Colorectal Cancer Tests

2018-07-16 globenewswire - 2
MELBOURNE, Australia, July 16, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (Nasdaq:GENE) (“Company”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, announced today that both its new breast cancer and colorectal cancer risk assessment tests are on track for release in October 2018. In addition the company has already commenced development of other cancer and disease targets for its predictive technologies.
GTG GNTLF GENE

16
Genetic Technologies Announces Heads of Agreement with Swisstec

2018-06-19 globenewswire - 2
MELBOURNE, Australia, June 19, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (Nasdaq:GENE) (“Company”, “GTG”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has entered into a Heads of Agreement with Swisstec Health Analytics Ltd. (“Swisstec”) to work together over the next 30 days to finalise a Proposed Joint Venture (PJV) to establish a new Company, (“JV Company”).
GTG GNTLF GENE

14
Genetic Technologies Announces Binding Project Shivom Agreement

2018-06-07 globenewswire
MELBOURNE, Australia, June 07, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (Nasdaq:GENE), “Company”, “GTG”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has entered into a binding agreement (“Agreement”) with Omix Ventures Private Limited (“Project Shivom”), formalising the business relationship originally documented in the non-binding terms sheet previously announced to the market on 6 March 2018.
GTG GNTLF GENE

15
Genetic Technologies Announces Grant from NHMRC Awarded to University of Melbourne to Substantially Improve Breast Cancer Risk Prediction and Increase Accessibility 

2018-05-01 globenewswire
MELBOURNE, Australia, May 01, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (Nasdaq:GENE) (“Company”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce the award of an NHMRC Partnership Grant to a research team led by Professor John Hopper from the Centre for Epidemiology and Biostatistics, Melbourne School of Population & Global Health at The University of Melbourne.
GTG GNTLF GLH GENE

15
Genetic Technologies Limited Announces Further Collaborative Research with The University of Melbourne to Broaden the Applicability of the BREVAGenplus® Breast Cancer Risk Assessment Test

2018-03-16 globenewswire - 1
MELBOURNE, Australia, March 16, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (Nasdaq:GENE) (“Company”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, announced today the execution of a research and services agreement with The University of Melbourne for the further development and enhancement of the BREVAGenplus breast cancer risk assessment test.
GTG GNTLF GENE

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to ASX:GTG / GENETIC TECHNOLOGIES LIMITED on message board site Silicon Investor.

IGTG - Ingen Technologies, Inc. IGTG - Ingen Technologies, Inc. IGTG - Ingen Technologies, Inc. GTGO GTGO GTGO
Group Telecom - GTG.B - on Toronto and GTTLB - on NASDAQ Group Telecom - GTG.B - on Toronto and GTTLB - on NASDAQ Group Telecom - GTG.B - on Toronto and GTTLB - on NASDAQ